Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
15.47
-0.33 (-2.09%)
At close: Jun 23, 2025, 4:00 PM
15.60
+0.13 (0.84%)
After-hours: Jun 23, 2025, 5:12 PM EDT
Company Description
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases.
It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren’s disease; and batoclimab for graves' disease and thyroid eye disease.
The company has a license agreement with HanAll Biopharma Co., Ltd. for the rights of intellectual property relating to IMVT-1402 and batoclimab.
Immunovant, Inc. was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Immunovant, Inc.
Country | United States |
Founded | 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 362 |
CEO | Eric Venker |
Contact Details
Address: 320 West 37th Street, 6th Floor New York, New York 10018 United States | |
Phone | 917 580 3099 |
Website | immunovant.com |
Stock Details
Ticker Symbol | IMVT |
Exchange | NASDAQ |
Fiscal Year | April - March |
Reporting Currency | USD |
CIK Code | 0001764013 |
CUSIP Number | 45258J102 |
ISIN Number | US45258J1025 |
Employer ID | 83-2771572 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Eric Venker M.D., Pharm.D. | Chief Executive Officer and Director |
Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board |
Dr. Jay S. Stout Ph.D. | Chief Technology Officer |
Tiago M. Girao CPA | Chief Financial Officer |
Melanie Gloria B.S.N. | Chief Operating Officer |
Christopher A. Van Tuyl Esq., J.D. | Chief Legal Officer and Corporate Secretary |
Lauren Schrier M.B.A. | Vice President of Marketing |
Christine Blodgett | Senior Vice President of Human Resources |
Andy Deig | Senior Vice President of Strategic Finance |
Dr. Michael Geffner M.B.A., M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 13, 2025 | 144 | Filing |
Jun 3, 2025 | 144 | Filing |
May 29, 2025 | 10-K | Annual Report |
May 29, 2025 | 8-K | Current Report |
May 21, 2025 | 144 | Filing |
May 19, 2025 | 144 | Filing |
Apr 30, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
Apr 21, 2025 | SCHEDULE 13D/A | Filing |
Apr 21, 2025 | 8-K | Current Report |
Mar 26, 2025 | SCHEDULE 13G | Filing |